EOLS Stock Overview
A performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Evolus, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.99 |
| 52 Week High | US$17.82 |
| 52 Week Low | US$9.24 |
| Beta | 1.31 |
| 11 Month Change | -27.86% |
| 3 Month Change | -18.66% |
| 1 Year Change | 21.85% |
| 33 Year Change | 94.96% |
| 5 Year Change | -15.56% |
| Change since IPO | 4.26% |
Recent News & Updates
Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26%
Nov 13
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?
Oct 22Evolus Continues To Make Progress
Aug 02Recent updates
Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26%
Nov 13Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?
Oct 22Evolus Continues To Make Progress
Aug 02Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump
Aug 02Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt
Jul 13Evolus: Chiseling Away At The Aesthetic Market
May 22Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results
May 10Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028
Mar 20The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts
Mar 10Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Jan 18Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up
Jan 18Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?
Jun 16Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?
Nov 06Evolus concludes certain royalty payments related to settlement of IP rights dispute
Sep 21Evolus: Turning That Frown Upside Down
Sep 11Evolus appoints Experian's exec as CFO
Aug 30Is Evolus (NASDAQ:EOLS) Using Too Much Debt?
Aug 04Evolus Q2 2022 Earnings Preview
Aug 01Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?
Mar 21Shareholder Returns
| EOLS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.6% | -7.0% | -2.1% |
| 1Y | 21.8% | 8.5% | 29.7% |
Return vs Industry: EOLS exceeded the US Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: EOLS underperformed the US Market which returned 29.6% over the past year.
Price Volatility
| EOLS volatility | |
|---|---|
| EOLS Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EOLS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EOLS's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 322 | David Moatazedi | www.evolus.com |
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names.
Evolus, Inc. Fundamentals Summary
| EOLS fundamental statistics | |
|---|---|
| Market cap | US$766.82m |
| Earnings (TTM) | -US$55.46m |
| Revenue (TTM) | US$248.33m |
3.1x
P/S Ratio-13.7x
P/E RatioIs EOLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EOLS income statement (TTM) | |
|---|---|
| Revenue | US$248.33m |
| Cost of Revenue | US$74.64m |
| Gross Profit | US$173.69m |
| Other Expenses | US$229.15m |
| Earnings | -US$55.46m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 69.94% |
| Net Profit Margin | -22.33% |
| Debt/Equity Ratio | 2,057.9% |
How did EOLS perform over the long term?
See historical performance and comparison